Saqib Javed
Leighton Hospital NHS Foundation Trust, U.K.
Title: Histoscanningâ„¢ for detection of prostate cancer: Does it have any role in routine clinical practice?
Biography
Biography: Saqib Javed
Abstract
Prostate HistoscanningTM (PHS) is a trans-rectal ultrasound (TRUS) based technology that scans the prostate gland sequentially using a TRUS probe. PHS software then analyses back-scattered radiofrequency data following the TRUS scan. The manufacturers claim that PHS can distinguish between benign and malignant tissue based on their radiofrequency signature. Initial reports showed encouraging results with PHS. Subsequent studies were unable to reproduce these findings. Various studies were performed comparing PHS with TRUS biopsies, trans-perineal template guided biopsies, whole mount radical prostatectomy specimens and multiparametric magnetic resonant imaging. Initial studies in 2008 (Braeckman et al) and 2012 (Simmons et al) showed encouraging results for PHS in detection of prostate cancer. These studies included small number of highly selected patients and were un-blinded. More recently in 2014 (Javed et al) and 2015 (Porres et al), blinded studies of unselected and higher number of patients were performed in routine clinical practice that showed the inability of PHS to detect prostate cancer. Conclusion: Initial small and un-blinded studies on PHS reported encouraging results. However, subsequent independent and blinded studies with larger patient cohorts did not reproduce these findings and revealed that PHS failed to identify prostate cancer in routine clinical practice.